Although dasatinib led to significant inhibition of BCR-ABL kinase activity, the most primitive quiescent CML LSCs (Lin-CD34+CD38-) were resistant to dasatinib treatment [19]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.